These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 30601976

  • 1. Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial.
    Hocqueloux L, Raffi F, Prazuck T, Bernard L, Sunder S, Esnault JL, Rey D, Le Moal G, Roncato-Saberan M, André M, Billaud E, Valéry A, Avettand-Fènoël V, Parienti JJ, Allavena C, MONCAY study group.
    Clin Infect Dis; 2019 Oct 15; 69(9):1498-1505. PubMed ID: 30601976
    [Abstract] [Full Text] [Related]

  • 2. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
    Trottier B, Lake JE, Logue K, Brinson C, Santiago L, Brennan C, Koteff JA, Wynne B, Hopking J, Granier C, Aboud M.
    Antivir Ther; 2017 Oct 15; 22(4):295-305. PubMed ID: 28401876
    [Abstract] [Full Text] [Related]

  • 3. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
    Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G, SINGLE Investigators.
    N Engl J Med; 2013 Nov 07; 369(19):1807-18. PubMed ID: 24195548
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
    Llibre JM, Brites C, Cheng CY, Osiyemi O, Galera C, Hocqueloux L, Maggiolo F, Degen O, Taylor S, Blair E, Man C, Wynne B, Oyee J, Underwood M, Curtis L, Bontempo G, van Wyk J.
    Clin Infect Dis; 2023 Feb 18; 76(4):720-729. PubMed ID: 35235656
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
    van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla Sogorb J, Routy JP, Wyen C, Ait-Khaled M, Nascimento MC, Pappa KA, Wang R, Wright J, Tenorio AR, Wynne B, Aboud M, Gartland MJ, Smith KY.
    Clin Infect Dis; 2020 Nov 05; 71(8):1920-1929. PubMed ID: 31905383
    [Abstract] [Full Text] [Related]

  • 6. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
    Galizzi N, Poli A, Galli L, Muccini C, Mastrangelo A, Dell'Acqua R, Maillard M, Bossolasco S, Cinque P, Lazzarin A, Castagna A, Gianotti N.
    Int J Antimicrob Agents; 2020 Mar 05; 55(3):105893. PubMed ID: 31926287
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
    Rodriguez-Gonzalez CG, Chamorro-de-Vega E, Ortega-Navarro C, Alonso R, Herranz-Alonso A, Sanjurjo-Saez M.
    Ann Pharmacother; 2020 Jul 05; 54(7):633-643. PubMed ID: 31910643
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
    Osiyemi O, De Wit S, Ajana F, Bisshop F, Portilla J, Routy JP, Wyen C, Ait-Khaled M, Leone P, Pappa KA, Wang R, Wright J, George N, Wynne B, Aboud M, van Wyk J, Smith KY.
    Clin Infect Dis; 2022 Sep 29; 75(6):975-986. PubMed ID: 35079789
    [Abstract] [Full Text] [Related]

  • 9. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
    Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, Weinstein MC, Paltiel AD, Walensky RP.
    Clin Infect Dis; 2016 Mar 15; 62(6):784-91. PubMed ID: 26658053
    [Abstract] [Full Text] [Related]

  • 10. Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.
    Tremblay G, Chounta V, Piercy J, Holbrook T, Garib SA, Bukin EK, Punekar YS.
    Value Health Reg Issues; 2018 Sep 15; 16():74-80. PubMed ID: 30296624
    [Abstract] [Full Text] [Related]

  • 11. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
    Hidalgo-Tenorio C, Cortés LL, Gutiérrez A, Santos J, Omar M, Gálvez C, Sequera S, Jesús SE, Téllez F, Fernández E, García C, Pasquau J.
    Medicine (Baltimore); 2019 Aug 15; 98(32):e16813. PubMed ID: 31393412
    [Abstract] [Full Text] [Related]

  • 12. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.
    Blanco JL, Rojas J, Paredes R, Negredo E, Mallolas J, Casadella M, Clotet B, Gatell JM, de Lazzari E, Martinez E, DOLAM Study Team.
    J Antimicrob Chemother; 2018 Jul 01; 73(7):1965-1971. PubMed ID: 29608685
    [Abstract] [Full Text] [Related]

  • 13. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis.
    Michienzi SM, Schriever CA, Badowski ME.
    Int J STD AIDS; 2019 Feb 01; 30(2):181-187. PubMed ID: 30381029
    [Abstract] [Full Text] [Related]

  • 14. An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.
    Evitt LA, Nanji S, Grove RA, Okoli C, van Wyk J, Snedecor SJ.
    AIDS Res Ther; 2023 Mar 22; 20(1):17. PubMed ID: 36949442
    [Abstract] [Full Text] [Related]

  • 15. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients.
    Baldin G, Ciccullo A, Rusconi S, Capetti A, Sterrantino G, Colafigli M, d'Ettorre G, Giacometti A, Cossu MV, Borghetti A, Gennari W, Mussini C, Borghi V, Di Giambenedetto S.
    Int J Antimicrob Agents; 2019 Dec 22; 54(6):728-734. PubMed ID: 31521809
    [Abstract] [Full Text] [Related]

  • 16. Predictors of virological failure in HIV-1-infected patients switching to dolutegravir maintenance monotherapy.
    Wijting I, Rutsaert SL, Rokx C, Burger DM, Verbon A, van Kampen J, Boucher C, Rijnders B, Vandekerckhove L.
    HIV Med; 2019 Jan 22; 20(1):63-68. PubMed ID: 30270543
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain.
    Suárez-García I, Alejos B, Ruiz-Algueró M, García Yubero C, Moreno C, Bernal E, Pérez-Is L, Zubero Z, de Zárraga Fernández MA, Samperiz Abad G, Jarrín I, Cohort of the Spanish HIV/AIDS Research Network (CoRIS).
    J Int AIDS Soc; 2021 Jul 22; 24(7):e25758. PubMed ID: 34291580
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
    Sculier D, Wandeler G, Yerly S, Marinosci A, Stoeckle M, Bernasconi E, Braun DL, Vernazza P, Cavassini M, Buzzi M, Metzner KJ, Decosterd LA, Günthard HF, Schmid P, Limacher A, Egger M, Calmy A, Swiss HIV Cohort Study (SHCS).
    PLoS Med; 2020 Nov 22; 17(11):e1003421. PubMed ID: 33170863
    [Abstract] [Full Text] [Related]

  • 19. A retrospective clinical audit of general practices in Australia to determine the motivation for switch to dolutegravir/abacavir/lamivudine and clinical outcomes.
    Ferrer PE, Bloch M, Roth N, Finlayson R, Baker D, Koh K, Orth D, Urbaityte R, Brown D, Drummond F.
    Int J STD AIDS; 2018 Mar 22; 29(3):300-305. PubMed ID: 28901212
    [Abstract] [Full Text] [Related]

  • 20. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
    Raffi F, Rachlis A, Brinson C, Arasteh K, Górgolas M, Brennan C, Pappa K, Almond S, Granier C, Nichols WG, Cuffe RL, Eron J, Walmsley S.
    AIDS; 2015 Jan 14; 29(2):167-74. PubMed ID: 25387312
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.